MetaCap

Adagene Inc. ADR (ADAG)

NASDAQ: ADAGHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.76-0.25 (-12.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ADAG stock chart

Technical analysis

Key statistics

All statistics
Market cap
$118.17M
EPS (TTM)
-$0.37
52-week range
1.27 – 4.85
Day range
1.35 – 2.05
Volume / Avg
1.37M / 348.81K
Beta
—

52-week range

$1.27$4.85

ADAG stock today

Shares of Adagene (ADAG) finished lower on Nov 20 at $1.76, a drop of 12.44% or $0.25 per share, versus the S&P 500's 3.70% decline. Volume was 3.9x the average at 1.37M shares, a sign of unusually heavy trading. Shares are 63.7% below their 52-week high of $4.85, set on Jul 1, 2026 and 38.9% above the 52-week low of $1.27, near the bottom of the past year's range.

ADAG is down 6.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 2.2%. Adagene has posted a net loss over the last twelve months (EPS of -$0.37), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Adagene

Company profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Peter P. Luo Ph.D.
Headquarters
Suzhou
Employees
128
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Adagene generated $7.7 million in revenue, up 7332.8% from fiscal 2024. Adagene reported a net loss of $17.6 million, compared with a loss of $33.4 million a year earlier. Operating margin was -279.5%.

Adagene annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.67M$103.20K$18.11M$9.29M$10.18M
Growth+7332.76%-99.43%+94.90%-8.67%+1351.71%
Net income$-17.61M$-33.42M$-18.95M$-79.97M$-73.18M
EPS (diluted)$-0.30$-0.59$-0.35$-1.48$-1.46

Analyst forecast

Forecast

Consensus (6 analysts)

none

Avg. price target

$9.91+463.07%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $17.45

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

ADAG news

All ADAG news

Adagene peers

Health Care sector
ADAG peer companies
CompanyPrice% ChgMarket capCompare
MSLESatellos Bioscience Inc.5.68-2.07%$120.51Mvs ADAG
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs ADAG
MGNXMacroGenics Inc.1.96-1.01%$125.26Mvs ADAG
IMUXImmunic Inc.6.99-5.41%$111.01Mvs ADAG
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs ADAG
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs ADAG
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs ADAG
SIONSionna Therapeutics Inc.2.83-4.88%$127.79Mvs ADAG

Indexes, lists and sector

Adagene stock FAQ

What is Adagene's stock price today?

ADAG last traded at $1.76 as of Nov 20, 4:00 PM EST, down 12.44% on the day. Prices are delayed at least 15 minutes.

Who is Adagene's CEO?

Dr. Peter P. Luo Ph.D. is the chief executive officer of Adagene Inc. ADR, which has about 128 employees.

What is the ADAG 52-week high?

The 52-week high for ADAG is $4.85 and the 52-week low is $1.27. The stock is currently 63.7% below its high.

Compare ADAG